Raymond James & Associates P Lx Pharma Inc. Transaction History

Raymond James & Associates

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$3.54 - $8.3 $235,615 - $552,431	-66,558 Closed	0 $0
Q4 2021 Feb 08, 2022	SELL	$7.69 - $19.66 $231,169 - $590,999	-30,061 Reduced 31.11%	66,558 $533,000
Q3 2021 Nov 02, 2021	BUY	$12.22 - $21.28 $74,407 - $129,573	6,089 Added 6.73%	96,619 $1.87 Million
Q2 2021 Aug 11, 2021	SELL	$9.0 - $15.94 $100,647 - $178,257	-11,183 Reduced 10.99%	90,530 $1.25 Million
Q1 2021 May 14, 2021	BUY	$5.24 - $10.14 $532,976 - $1.03 Million	101,713 New	101,713 $918,000

Q3 2018 Nov 14, 2018	SELL	$3.18 - $5.15 $33,224 - $53,807	-10,448 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$3.3 - $4.5 $5,550 - $7,569	-1,682 Reduced 13.87%	10,448 $41,000
Q1 2018 May 14, 2018	BUY	$3.2 - $7.43 $1,600 - $3,715	500 Added 4.3%	12,130 $41,000
Q4 2017 Feb 14, 2018	BUY	$6.3 - $9.1 $73,269 - $105,833	11,630	11,630 $80,000

61.6K

Ticker PLXP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 29,137,700
Description
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other asp...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.